*/
© Shutterstock
Marie Law, Director of Toxicology at AlphaBiolabs, examines the latest ONS data on drug misuse and its implications for toxicology testing in family law cases
Substance misuse continues to play a significant role in family law proceedings, influencing decisions around safeguarding, parenting capacity and contact arrangements.
The latest Office for National Statistics (ONS) data confirms that drug use remains widespread, with millions of adults reporting recent use.
Although overall prevalence has remained broadly stable, the scale of misuse and changing profile of substances involved continue to present challenges for courts, reinforcing the need for proportionate, evidence-based drug testing in family proceedings.
The latest ONS figures underline the continued prevalence of drug misuse across England and Wales.
For the year ending March 2025:
While these levels have not increased markedly, they have also failed to decline, indicating that drug misuse remains a persistent issue.
For family courts, this translates into a steady flow of cases where historic or ongoing drug use must be carefully assessed.
The ONS data also challenges long-standing assumptions about who is most likely to misuse drugs. While younger adults continue to report the highest levels of use, there have been increases among older age groups (eg aged 45-54).
This shift is significant for family law, where substance misuse may arise in cases involving older parents or carers.
Socio-economic trends further complicate the picture, with higher rates of Class A drug use reported among higher-income households, undermining assumptions that serious drug misuse is confined to economically deprived groups.
For legal practitioners, these findings reinforce the importance of avoiding assumptions based on age, income or lifestyle. Instead, objective, court-admissible drug testing remains essential to accurately assess risk and safeguarding concerns.
Established substances continue to dominate patterns of misuse.
However, prevalence data alone does not fully reflect the complexity encountered in family law cases. In practice, courts are increasingly dealing with misuse of controlled prescription medications, new psychoactive substances and poly-drug combinations, many of which are not routinely included in standard testing panels.
This is particularly relevant where substances are taken without full awareness of their composition, or where prescribed drugs are misused, complicating disclosure and risk assessment.
Reliance on standard testing panels alone no longer provides a sufficiently accurate picture of an individual’s substance use, particularly where non-standard drugs or poly-drug use are involved.
In family proceedings, a narrow testing scope may fail to identify habitual or problematic use outside standard panels.
Additionally, symptoms of drug use often overlap across different substances, meaning that symptoms alone cannot be used to determine which drugs to test for.
Drug misuse remains a persistent feature of life in England and Wales, with patterns of use that are broad and increasingly complex. As drug use diversifies, testing strategies must evolve accordingly.
Substance misuse continues to play a significant role in family law proceedings, influencing decisions around safeguarding, parenting capacity and contact arrangements.
The latest Office for National Statistics (ONS) data confirms that drug use remains widespread, with millions of adults reporting recent use.
Although overall prevalence has remained broadly stable, the scale of misuse and changing profile of substances involved continue to present challenges for courts, reinforcing the need for proportionate, evidence-based drug testing in family proceedings.
The latest ONS figures underline the continued prevalence of drug misuse across England and Wales.
For the year ending March 2025:
While these levels have not increased markedly, they have also failed to decline, indicating that drug misuse remains a persistent issue.
For family courts, this translates into a steady flow of cases where historic or ongoing drug use must be carefully assessed.
The ONS data also challenges long-standing assumptions about who is most likely to misuse drugs. While younger adults continue to report the highest levels of use, there have been increases among older age groups (eg aged 45-54).
This shift is significant for family law, where substance misuse may arise in cases involving older parents or carers.
Socio-economic trends further complicate the picture, with higher rates of Class A drug use reported among higher-income households, undermining assumptions that serious drug misuse is confined to economically deprived groups.
For legal practitioners, these findings reinforce the importance of avoiding assumptions based on age, income or lifestyle. Instead, objective, court-admissible drug testing remains essential to accurately assess risk and safeguarding concerns.
Established substances continue to dominate patterns of misuse.
However, prevalence data alone does not fully reflect the complexity encountered in family law cases. In practice, courts are increasingly dealing with misuse of controlled prescription medications, new psychoactive substances and poly-drug combinations, many of which are not routinely included in standard testing panels.
This is particularly relevant where substances are taken without full awareness of their composition, or where prescribed drugs are misused, complicating disclosure and risk assessment.
Reliance on standard testing panels alone no longer provides a sufficiently accurate picture of an individual’s substance use, particularly where non-standard drugs or poly-drug use are involved.
In family proceedings, a narrow testing scope may fail to identify habitual or problematic use outside standard panels.
Additionally, symptoms of drug use often overlap across different substances, meaning that symptoms alone cannot be used to determine which drugs to test for.
Drug misuse remains a persistent feature of life in England and Wales, with patterns of use that are broad and increasingly complex. As drug use diversifies, testing strategies must evolve accordingly.
Marie Law, Director of Toxicology at AlphaBiolabs, examines the latest ONS data on drug misuse and its implications for toxicology testing in family law cases
Update from the Chair of the Bar
By Clement Cowley, Partner at The Penny Group
Modernising communication and collaboration at a leading Chancery set. A Zexi case study
How to build profile without compromising professional duties. By Naumaan Farooq, Co-Founder of Inked PR
Marie Law, Director of Toxicology at AlphaBiolabs, examines the role of cut-off levels, and the wider range of factors that must be considered when interpreting results for family court proceedings
Endometriosis Awareness North, a charity raising awareness of endometriosis and supporting those affected across the North of England, has received a £500 boost from AlphaBiolabs via the company’s Giving Back initiative
A decade of reviews and research has disrupted accepted thinking in the search for causality. Suicides following abuse have overtaken domestic homicides. Is the law keeping up? Professor Susan Edwards KC (Hon) examines recent cases and the obstacles to successful prosecution
The case against judge-only justice – and why efficiency is not enough. By Professor Leslie Thomas KC
Heritage as an anchor and a compass, finding our common humanity and embracing the power of the outsider – Melina Antoniadis’s lessons learnt
Seeing the full picture – Baljit Ubhey OBE outlines the CPS action plan to tackle violence against women and girls, offering insights directly relevant to courtroom practice
Lauren Fullerton examines the how, what and why of setting up a second chambers base
